Cytokinetics (UK) Limited

Cytokinetics (UK) Limited is focused on advancing treatments for serious diseases in the field of cardiovascular medicine. The company is currently preparing for the UK launch of MYQORZO, a treatment for obstructive hypertrophic cardiomyopathy, highlighting its commitment to innovative medical solutions. With a strong emphasis on collaboration and strategic medical affairs, Cytokinetics (UK) Limited plays a vital role in the healthcare landscape.